Epirium’s small molecule inhibitors target an endogenous pathway that is induced following muscle injury and coordinates the injury repair process and ensures effective regeneration of functional muscle. Our lead candidates utilize the body’s own natural biological repair processes to repair and restore tissues, thus slowing down the progressive degenerative processes that underlie a wide range of muscle–related diseases. We believe our unique mechanism of action and novel small molecules have potential for broad clinical applicability across a number of therapeutic areas. Increasing PGE2 through inhibition of 15-PGDH, the metabolizing enzyme of PGE2. Target it MF-NCE1